More large trials needed to decide best duration of treatment with tamoxifen

被引：1

作者：

Cameron, DA ^{[1
]}

机构：

[1] Western Gen Hosp, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland

来源：

BRITISH MEDICAL JOURNAL | 1998年 / 317卷 / 7171期

关键词：

D O I：

10.1136/bmj.317.7171.1524

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1524 / 1524

页数：1

共 5 条

[1]

Clarke M, 1998, LANCET, V351, P1451

[2] Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J].

Fisher, B ;

Dignam, J ;

Bryant, J ;

DeCillis, A ;

Wickerham, DL ;

Wolmark, N ;

Costantino, J ;

Redmond, C ;

Fisher, ER ;

Bowman, DM ;

Deschenes, L ;

Dimitrov, NV ;

Margolese, RG ;

Robidoux, A ;

Shibata, H ;

Terz, J ;

Paterson, AHG ;

Feldman, MI ;

Farrar, W ;

Evans, J ;

Lickley, HL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1529-1542

[3] Adjuvant tamoxifen: how long before we know how long? [J].

Rea, D ;

Poole, C ;

Gray, R .

BRITISH MEDICAL JOURNAL, 1998, 316 (7143) :1518-1519

[4] Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer [J].

Stewart, HJ ;

Forrest, AP ;

Everington, D ;

McDonald, CC ;

Dewar, JA ;

Hawkins, RA ;

Prescott, RJ ;

George, WD .

BRITISH JOURNAL OF CANCER, 1996, 74 (02) :297-299

[5] Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer [J].

Tormey, DC ;

Gray, R ;

Falkson, HC .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (24) :1828-1833

← 1 →